Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.


Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX.pa), a bio pharmaceutical company and the leader in NOX therapies, announced today that it has begun enrolling patients into the Company’s Phase 2 clinical trial of GKT831, its NOX1 and NOX4 enzymes inhibitor, in primary biliary cholangitis (PBC). Enrollment initiation at the first investigational center in the U.S. took place following regulatory clearance by the U.S. Food & Drug Administration and local Institutional Review Board.  Dosing of the first patient is expected shortly.

Genkyotex is currently working on the activation of a large network of investigational centers participating in this global trial.  In total, over 50 centers are expected to be activated in the United States, Canada and several European countries.  Interim top-line results from the Phase 2 clinical trial are anticipated in the first half of 2018, and full results are expected in the second half of 2018.

We are pleased to initiate patient recruitment for this promising clinical trial,” said Philippe Wiesel, MD, Executive Vice President and Chief Medical Officer of Genkyotex. “Alleviating progressive liver injury and fibrosis is an important therapeutic objective in patients with active PBC.We are grateful to the global network of experienced investigators who will participate in this important Phase 2 clinical study. We are now focused on delivering trial results over the next 18 months.

The Phase 2 clinical trial is a 24-week, double-blind, placebo controlled, multi-center trial evaluating the safety and efficacy of GKT831 in patients with PBC and inadequate response to ursodeoxycholic acid. A total of 102 PBC patients will be enrolled in this international study and allocated to placebo or one of two doses of GKT831 (400mg once a day or 400mg twice a day). The primary objective of the trial will be to demonstrate therapeutic activity through a reduction of gamma glutamyltranspeptidade, a marker of liver injury, which also reflects oxidative stress. Secondary efficacy endpoints include markers of liver inflammation and injury (CK-18, hs-CRP, ALT), non-invasive markers of liver fibrosis (Enhanced Liver Fibrosis score, transient elastography and circulating collagen fragments).

In addition, the trial will evaluate the effect of GKT831 on bile acid metabolism, itching, autoimmunity, and quality of life.  Moreover, the trial will characterize the clinical safety profile and pharmacokinetics of GKT831 in this patient population.  An interim analysis will be performed once 90 patients have completed their week 6 visit.